Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Open accessThe DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Abstract
: 1. After 50 years of antipsychotic drug development focused on the dopamine D2 receptor, schizophrenia remains a chronic, disabling disorder for most affected individuals. 2. Studies over the last decade demonstrate that administration of low doses of NMDA receptor antagonists can cause in normal subjects the negative symptoms, cognitive impairments and physiologic disturbances observed in schizophrenia. 3. Furthermore, a number of recently identified risk genes for schizophrenia affect NMDA receptor function or glutamatergic neurotransmission. 4. Placebo-controlled trials with agents that directly or indirectly activate the glycine modulatory site on the NMDA receptor have shown reduction in negative symptoms, improvement in cognition and in some cases reduction in positive symptoms in schizophrenic patients receiving concurrent antipsychotic medications. 5. Thus, hypofunction of the NMDA receptor, possibly on critical GABAergic inter-neurons, may contribute to the pathophysiology of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
From Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies (2008) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The prefrontal cortex (PFC) and hippocampus stand out as major regions affected in schizophrenia”
From Adolescent Onset of Cortical Disinhibition in Schizophrenia: Insights From Animal Models (2011) · cites this paper as [3]
In the citing paper
“A loss of scaffolding proteins in spines could alter glutamatergic receptor signaling, disruption of which is theorized to contribute to the etiology of schizophrenia60.”
From Dendritic spine pathology in neuropsychiatric disorders (2011) · cites this paper as [60]
In the citing paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
From Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies (2008) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · cited 1×
“Existing drugs are poorly tolerated and exhibit little differences in efficacy (Lieberman et al., 2005).”
BackgroundKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 2×
“Newcomer et al. (1999) extended the findings of Krystal et al. (1994) by showing that declarative memory, the form impaired in schizophrenia, was quite sensitive to low dose ketamine infusion.”
BackgroundRecent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · cited 1×
“Based upon the emerging pharmacology of the NMDAR, Javitt and Zukin (1991) proposed that the psychotomimetic effects of PCP were due to blockade of the NMDA receptors.”
BackgroundTripartite synapses: glia, the unacknowledged partner
Araque, A., Parpura, V., Sanzgiri, R. P., & Haydon, P. G. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01349-6 · Cited by 2,529 · cited 1×
“The glutamatergic synapse consists of a tight functional relationship among the presynaptic terminal, the postsynaptic spine and the ensheathing astrocyte end-foot (Araque et al., 1999; Coyle et al., 2002).”
BackgroundSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
The hippocampal-VTA loop: controlling the entry of information into long-term memory
Lisman, J. E., & Grace, A. A. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.002 · Cited by 1,983
Braff, D. L., Geyer, M. A., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100810 · Cited by 1,705
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393 · cited 2×
“In addition, clozapine treatment has been associated with reduction in the rate of suicide, reduction in smoking and reduction in abuse of other substances in schizophrenic patients (Drake et al., 2000; Meltzer et al., 2003; Zimmet et al., 2000).”
BackgroundLesion of striatal neurons with kainic acid provides a model for Huntington's chorea
COYLE, J. T., & SCHWARCZ, R. (1976) · Nature · doi:10.1038/263244a0 · Cited by 1,248 · cited 1×
“We focused on glutamatergic signal transduction before there was any evidence that it could be relevant to neuropsychiatric disorders (Coyle and Schwarcz, 1976).”
BackgroundSelf-citation
Research works printed but not linked: 1
- Wang, X., He, G., Gu, N., Yang, J., Tang, J., Chen, Q., et al. (2004). Association of G72/G30 with schizophrenia in the Chinese population. Biochem. Biophys. Res. Commun.319:1281–1286. [DOI] [PubMed] [Google Scholar] · DOI
Cited by
Items 401–500 of 954
Sun, L., Li, J., Zhou, K., Zhang, M., Yang, J., Li, Y., Ji, B., Zhang, Z., Zhu, H., Yang, L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060598 · Cited by 35
“The glutamate hypothesis focusing on N-methylD-aspartate (NMDA) glutamate receptor hypofunction has shown a number of promising leads [4].”
BackgroundUltrastructural evidence for glutamatergic dysregulation in schizophrenia
Roberts, R. C., McCollum, L. A., Schoonover, K. E., Mabry, S. J., Roche, J. K., & Lahti, A. C. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.01.016 · Cited by 37
“Evidence from in vivo imaging, postmortem studies and animal models of schizophrenia implicate the glutamatergic system in schizophrenia (Coyle, 2006; Goff and Coyle, 2001; Javitt, 2004; Krystal, 2008).”
BackgroundÖzdemir, V., Jamal, M. M., Ősapay, K., Jadus, M. R., Sandor, Z., Hashemzadeh, M., & Szabó, S. (2007) · Journal of Investigative Medicine · doi:10.2310/6650.2007.00014 · Cited by 33
“Moreover, the neurobiology of schizophrenia is complex, and neurotransmitter systems beyond dopamine (eg, glutamate system) and host–environment interactions are likely to be involved.(22,23) The observations made in our study are in agreement, however, with several converging lines of evidence, including (1) the cyto…”
Resultd -serine and schizophrenia: an update
Nunes, E. A., MacKenzie, E. M., Rossolatos, D., Perez-Parada, J., Baker, G. B., & Dursun, S. M. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.65 · Cited by 35
“8 Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia.”
BackgroundInfluentialYang, S., Hong, C., Huang, Y.-H., & Tsai, S. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.11.058 · Cited by 33
Atagün, M. İ., Şıkoğlu, E. M., Can, S. S., Karakaş-Uğurlu, G., Ulusoy-Kaymak, S., Çayköylü, A., Algın, O., Phillips, M. L., Moore, C. M., & Öngür, D. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.11.012 · Cited by 35
“Genome wide association studies have identified shared risk genes in schizophrenia and bipolar disorder involving glutamatergicmetabolism and cascades (see review; Coyle, 2006), which are in line with the glutamatergic abnormalities we have observed.”
BackgroundAttractor Network Dynamics, Transmitters, and Memory and Cognitive Changes in Aging
Rolls, E. T. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108554350.014 · Cited by 73
Brain oscillations in bipolar disorder and lithium-induced changes
Atagün, M. İ. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s100597 · Cited by 36
“DISC-1, and these genes are abnormal in schizophrenia and bipolar disorder.(114) Wnt/β catenin,(115) Reelin,(116) and CDK(117)”
BackgroundSite of Action of Brain Neurosteroid Pregnenolone Sulfate at the N-Methyl-D-Aspartate Receptor
Krausová, B. H., Kysilov, B., Černý, J., Vyklický, V., Smejkalová, T., Ladislav, M., Balík, A., Kořínek, M., Chodounská, H., Kudová, E., et al. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.3010-19.2020 · Cited by 33
“, 1959) mimicking schizophrenia in humans (Tamminga, 1998; Coyle, 2006).”
BackgroundA Case for Thalamic Mechanisms of Schizophrenia: Perspective From Modeling 22q11.2 Deletion Syndrome
Jiang, Y., Patton, M. H., & Zakharenko, S. S. (2021) · Frontiers in Neural Circuits · doi:10.3389/fncir.2021.769969 · Cited by 33
“…IN SCHIZOPHRENIA: THALAMIC INVOLVEMENT The most prominent theories of schizophrenia symptoms include the dopamine hyperfunction hypothesis (Carlsson, 1988), the glutamate hypofunction theory (Coyle, 1996, 2006), and the disconnectivity hypothesis (Friston and Frith, 1995; Woodward et al., 2012).”
BackgroundKrzystanek, M., Bogus, K., Pałasz, A., Krzystanek, E., Worthington, J. J., & Wiaderkiewicz, R. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.01.017 · Cited by 35
Modulating neural plasticity with non-invasive brain stimulation in schizophrenia
Hasan, A., Wobrock, T., Rajji, T. K., Malchow, B., & Daskalakis, Z. J. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0446-8 · Cited by 34
Sood, P., Idris, N. F., Cole, S. M., Grayson, B., Neill, J. C., & Young, A. M. J. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110387840 · Cited by 38
“…hypothesis of schizophrenia (Olney et al., 1999) have led to the use of PCP and other NMDA receptor antagonists to mimic symptomatology of schizophrenia in animals (reviewed in Coyle, 2006; Jentsch and Roth, 1999; Large, 2007, focusing on novel therapies; Morris et al., 2005; Mouri et al., 2007).”
BackgroundUmemori, J., Takao, K., Koshimizu, H., Hattori, S., Furuse, T., Wakana, S., & Miyakawa, T. (2013) · BMC Research Notes · doi:10.1186/1756-0500-6-203 · Cited by 32
“Dysfunction of glutamate signaling has been proposed to be involved in the etiology of schizophrenia [10-12].”
BackgroundEarly Life and Oxidative Stress in Psychiatric Disorders: What Can we Learn From Animal Models?
Mhillaj, E., Morgese, M. G., & Trabace, L. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150105122422 · Cited by 32
Candemir, E., Kollert, L., Weißflog, L., Geis, M., Müller, A., Post, A. M., O’Leary, A., Harro, J., Reif, A., & Freudenberg, F. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.01.008 · Cited by 38
“Studies in animals and humans targeting the N-methyl-Daspartate (NMDA) receptor revealed that NMDA receptor hypofunction is an important contributor to these treatment-resistant symptoms (reviewed in Coyle, 2006).”
Pérez-Rando, M., Castillo-Gómez, E., Guirado, R., Blasco‐Ibáñez, J. M., Crespo, C., Varea, E., & Nácher, J. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00166 · Cited by 36
“Different studies point to this hypofunction as a factor contributing to alterations of fast-spiking neurons in schizophrenia (Coyle, 2006; Lisman et al., 2008), but alterations of these receptors in other interneuronal populations could also result in an abnormal functioning or connectivity.”
BackgroundBrown, H. E., Freudenreich, O., Fan, X., Heard, S. O., GOFF, D. C., Petrides, G., Harrington, A., Kane, J. M., Judge, H., Hoeppner, B. B., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.0151 · Cited by 33
Developing zebrafish experimental animal models relevant to schizophrenia
Demin, K. A., Мешалкина, Д. А., Volgin, A. D., Yakovlev, O. V., de Abreu, M. S., Alekseeva, P. A., Friend, A. J., Lakstygal, A. M., Zabegalov, K. N., Amstislavskaya, T. G., et al. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.07.017 · Cited by 34
Animal Models of Schizophrenia
Yanagi, M., Southcott, S. A., Lister, J. M., & Tamminga, C. A. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-394596-9.00012-3 · Cited by 32
Critical role of nitric oxide in the modulation of prepulse inhibition in Swiss mice
Issy, A. C., Pedrazzi, J. F. C., Yoneyama, B. H., & Bel, E. A. D. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3277-4 · Cited by 32
“However, dysfunctional NMDA glutamate receptors cause disinhibition of the pyramidal glutamatergic neurons through the GABAergic interneurons, which could result in an increase in the firing of dopaminergic neurons (for review, see Coyle 2006).”
BackgroundDong, B., Yang, Y., Han, D., & Wang, Y. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1174738 · Cited by 37
“N-methyl-D-aspartate receptor hypofunction is a convergence point for the progression and symptoms of SZ, especially cognitive deficits (Moghaddam, 2003; Coyle, 2006; Lisman et al., 2008; Marek, 2010; Snyder et al., 2013; Cohen et al., 2015; Nakazawa et al., 2017).”
BackgroundAntagonism at serotonin 5-HT2A receptors modulates functional activity of frontohippocampal circuit
Gozzi, A., Crestan, V., Turrini, G., Clemens, M., & Bifone, A. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1772-4 · Cited by 34
Xiong, J., Wei, B., Li, Y., Zhan, J., Jiang, S., Chen, H., Yan, K., Yu, B., & Yang, Y. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4923-7 · Cited by 34
Potential role of adenosine A2A receptors in the treatment of schizophrenia
Wardas, J. (2008) · Frontiers in bioscience · doi:10.2741/2995 · Cited by 36
“that schizophrenia is a heterogeneous group of disorders and suggests the lack of a single molecular event which could explain its pathophysiology (1, 2).”
BackgroundResultInfluentialImpact of neuroinflammation on brain glutamate and dopamine signalling in schizophrenia: an update
Nayak, U. Y., Manikkath, J., Arora, D. S., & Mudgal, J. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01548-3 · Cited by 34
“The glutamate released during the action potential is produced from glutamine supplied by astrocytes (Coyle 2006).”
NMDA receptor channel gating control by the pre-M1 helix
McDaniel, M. J., Ogden, K. K., Kell, S. A., Burger, P. B., Liotta, D. C., & Traynelis, S. F. (2020) · The Journal of General Physiology · doi:10.1085/jgp.201912362 · Cited by 32
“…memory, have been implicated in the etiology of several neurological disorders, including epilepsy, intellectual disabilities, and schizophrenia (Coyle, 2006; Liu et al., 2004; Rice and DeLorenzo, 1998; Olney et al., 1999; Lemke et al., 2014; Traynelis et al., 2010; Yuan et al., 2015; XiangWei…”
BackgroundMood stabilizers increase prepulse inhibition in DBA/2NCrl mice
Flood, D. G., Choinski, M., Marino, M. J., & Ga̧sior, M. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1547-y · Cited by 32
Peripheral Glutamate Levels in Schizophrenia: Evidence from a Meta-Analysis
Song, J., Viggiano, A., Monda, M., & De Luca, V. (2014) · Neuropsychobiology · doi:10.1159/000364828 · Cited by 29
Liu, F., Zou, X., Sadovova, N., Zhang, X., Shi, L., Guo, L., Qian, F., Wen, Z., Patterson, T. A., Hanig, J. P., et al. (2010) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2010.07.234 · Cited by 35
“…to the 0736-5748/$36.00 Published by Elsevier Ltd on behalf of ISDN doi:10.1016/j.ijdevneu.2010.07.234 symptoms of schizophrenia, has provided the first compelling alter- native to the dopamine hypothesis, even a more important role in the endophenotype of schizophrenia than dopamine (Coyle, 2006).”
BackgroundInfluentialOyamada, Y., Horiguchi, M., Rajagopal, L., Miyauchi, M., & Meltzer, H. Y. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.09.040 · Cited by 33
Irmak, M. K. (2012) · Journal of Religion and Health · doi:10.1007/s10943-012-9673-y · Cited by 30
“Dopamine dysregulation is likely to be a secondary consequence of the primary biological causes of the condition (Coyle 2006).”
BackgroundDeveloping New Drugs for Schizophrenia: From Animals to the Clinic
Jones, D. N. C., Gartlon, J. E., Minassian, A., Perry, W., & Geyer, M. A. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00008-4 · Cited by 35
Molecular Pathogenesis of Anti-NMDAR Encephalitis
Ding, H., Jian, Z., Stary, C. M., Yi, W., & Xiong, X. (2015) · BioMed Research International · doi:10.1155/2015/643409 · Cited by 30
“NMDAR overactivity is the proposed underlying mechanism in epilepsy, dementia, and stroke, whereas decreased NMDAR activity results in symptoms of schizophrenia [29].”
Horiguchi, M., & Meltzer, H. Y. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.03.027 · Cited by 30
Turlington, M., Noetzel, M. J., Chun, A. C., Zhou, Y., Gogliotti, R. D., Nguyen, E. D., Gregory, K. J., Vinson, P. N., Rook, J. M., Gogi, K. K., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401028t · Cited by 29
Mabunga, D. F. N., Park, D., Ryu, O., Valencia, S. T., Adil, K. J., Kim, S., Kwon, K. J., Shin, C. Y., & Jeon, S. J. (2019) · Experimental Neurobiology · doi:10.5607/en.2019.28.6.697 · Cited by 29
“Most often, researchers interpret NMDAR antagonist-induced social behavior deficits as a model of negative symptoms of schizophrenia [9, 53, 54], lending further support to the NMDA receptor hypofunction hypothesis of schizophrenia [55].”
ResultA systematic review of TMS and neurophysiological biometrics in patients with schizophrenia
di Hou, M., Santoro, V., Biondi, A., Shergill, S. S., & Premoli, I. (2021) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.210006 · Cited by 30
“7 This has led to explorations of the role of glutamatergic 8 and γ -aminobutyric acid (GABA)–ergic neuro-transmission, which can both cause an altered excitation/ inhibition (E/I) balance.”
Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia
Munawar, N., Ahmad, A., Anwar, M. A., & Muhammad, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052625 · Cited by 32
“However, the changes observed in post-mortem studies might be the effects of chronic illness or consequences of treatment strategies rather than the cause of the disorder [15].”
BackgroundInfluentialExosomes in schizophrenia: Pathophysiological mechanisms, biomarkers, and therapeutic targets
Wang, Y., Amdanee, N., & Zhang, X. (2022) · European Psychiatry · doi:10.1192/j.eurpsy.2022.2319 · Cited by 31
“It was documented that an overexpression of miR-223 led to chronic hypofunction of theN-methyl-d-aspartate receptor (NMDAR) and lower synaptic activity [46].”
BackgroundFear extinction induced by activation of PKA ameliorates anxiety-like behavior in PTSD mice
Gao, F., Wang, J., Yang, S., Ji, M., & Zhu, G. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109306 · Cited by 31
Modulation of NMDA receptor function as a treatment for schizophrenia
Cioffi, C. L. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.07.019 · Cited by 36
Regulation of the cytoskeleton by Disrupted-in-Schizophrenia 1 (DISC1)
Wang, Q., & Brandon, N. J. (2011) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2011.06.004 · Cited by 36
“These studies suggest that DISC1 can potentially regulate actin cytoskeleton in dendritic spines, and link DISC1 strongly to the glutamate system which is known to be impaired in psychiatric disorders (Coyle, 2006).”
Frontal cortical synaptic communication is abnormal in Disc1 genetic mouse models of schizophrenia
Holley, S. M., Wang, E. A., Cepeda, C., Jentsch, J. D., Ross, C. A., Pletnikov, M. V., & Levine, M. S. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.02.007 · Cited by 33
“A major hypothesis of SZ proposes that hypofunction of the N-methyl-D-aspartate receptor (NMDAR) underlies the pathophysiology of SZ (Jentsch and Roth, 1999; Coyle, 2006).”
Popiolek, M., Ross, J. F., Charych, E. I., Chanda, P. K., Gundelfinger, E. D., Moss, S. J., Brandon, N. J., & Pausch, M. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.262063 · Cited by 31
Chen, Y., Bang, S., McMullen, M. F., Kazi, H., Talbot, K., Ho, M.-X., Carlson, G. C., Arnold, S. E., Ong, W.-Y., & Kim, S. F. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9773-x · Cited by 32
Atypical visual and somatosensory adaptation in schizophrenia-spectrum disorders
Andrade, G. N., Butler, J. S., Peters, G. A., Molholm, S., & Foxe, J. J. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.63 · Cited by 30
Murano, T., Hagihara, H., Tajinda, K., Matsumoto, M., & Miyakawa, T. (2019) · Communications Biology · doi:10.1038/s42003-018-0277-2 · Cited by 30
Neuroactive Amino Acid Profile in Autism Spectrum Disorder: Results from a Clinical Sample
Randazzo, M., Prato, A., Messina, M., Meli, C., Casabona, A., Rizzo, R., & Barone, R. M. E. (2023) · Children · doi:10.3390/children10020412 · Cited by 31
“Neur act ve AA changes have been described in psychiatric disorders that hav symptoms in common with ASD, such as cognitive impairment and issues with social interactions [5].”
BackgroundBakker, P. R., Bakker, E., Amin, N., van Duijn, C. M., van Os, J., & van Harten, P. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036561 · Cited by 30
“Various combinations of susceptibility genes may converge on synaptic processing in microcircuits, affecting a final common pathway of dysfunction and related symptoms, and secondary morphological alterations [40,41].”
BackgroundGono, T., Takarada, T., Fukumori, R., Kawaguchi, Y., Kaneko, H., Hanaoka, M., Katsumata, Y., Yoneda, Y., & Yamanaka, H. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30616 · Cited by 28
Kaphzan, H., O’Riordan, K. J., Mangan, K. P., Levenson, J. M., & Rosenblum, K. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000138 · Cited by 30
“in schizophrenia are related to either hypodopaminergic transmission in the frontal cortex [62], or to a decreased NMDA receptor functioning [63], and treatments tailored in that direction”
BackgroundPreweaning Sensorimotor Deficits and Adolescent Hypersociability in Grin1 Knockdown Mice
Moy, S. S., Nikolova, V. D., Riddick, N. V., Baker, L. K., & Koller, B. H. (2012) · Developmental Neuroscience · doi:10.1159/000337984 · Cited by 28
The immune system and schizophrenia: an update for clinicians
Upthegrove, R., & Barnes, N. M. (2014) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.113.011452 · Cited by 29
“We know that overactivity of NMDA receptors may provide a mechanism for epilepsy; conversely, low activity induces symptoms similar to schizophrenia (Coyle 2006; Dalmau 2008).”
BackgroundLoureiro, C. M., Shuhama, R., Fachim, H., Menezes, P. R., Del‐Ben, C. M., & Louzada‐Júnior, P. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.06.037 · Cited by 29
Brain Networks Reorganization During Maturation and Healthy Aging-Emphases for Resilience
González‐Escamilla, G., Muthuraman, M., Chirumamilla, V. C., Vogt, J., & Groppa, S. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00601 · Cited by 32
Saleem, T. H., Shehata, G. A., Toghan, R., Sakhr, H. M., Bakri, A. H., Desoky, T., Hamdan, F. R. A., Mohamed, N. F., & Hassan, M. H. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s233105 · Cited by 31
“If that does not happen it may result in neurological disorders, including ASD.58 β-alanine is essential for the formation of carnosine and anserine, both are functionally similar and act as antioxidants by capturing oxygen-free radicals.34 So βalanine deficiency among autistic children reported in the current study r…”
BackgroundInfluentialMicroRNAs suggest a new mechanism for altered brain gene expression in schizophrenia
Coyle, J. T. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813321106 · Cited by 29
Self-citationPatrich, E., Piontkewitz, Y., Peretz, A. S., Weiner, I., & Attali, B. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.08.021 · Cited by 32
Translating Human Genetics into Novel Treatment Targets for Schizophrenia
Schubert, C. R., Xi, H. S., Wendland, J. R., & O’Donnell, P. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.037 · Cited by 27
Autoantibodies and the Immune Hypothesis in Psychotic Brain Diseases: Challenges and Perspectives
Pathmanandavel, K., Starling, J., Dale, R. C., & Brilot, F. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/257184 · Cited by 27
Tsou, J. Y. (2012) · Studies in History and Philosophy of Science Part C Studies in History and Philosophy of Biological and Biomedical Sciences · doi:10.1016/j.shpsc.2012.01.003 · Cited by 32
“7 This has stimulated important research on the role of glutamate in schizophrenia (e.g., see Olney & Farber, 1995; Tamminga, 1998; Goff & Coyle, 2001; Carlsson et al., 2001; Laruelle, M., Kegeles, L. S., & Abi-Dargham, 2003; Coyle, 2006), which suggests that decreased glutamate activity (hypofunction) in the prefront…”
BackgroundVoluntary wheel running ameliorates symptoms of MK-801-induced schizophrenia in mice
Kim, T.-W., Kang, H., Park, J.-K., Lee, S., Baek, S.-B., & Kim, C. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2644 · Cited by 29
“Alterations in NMDA receptor function are implicated in the pathophysiology of numerous psychiatric diseases, including schizophrenia, major depression, posttraumatic stress disorder and alcoholism (9,10).”
Öngür, D., Haddad, S. A., Prescot, A. P., Jensen, J. E., Siburian, R., Cohen, B. M., Renshaw, P. F., & Smoller, J. W. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.01.033 · Cited by 29
Association of SNPs linked to increased expression of SLC1A1 with schizophrenia
Horiuchi, Y., Iida, S., Koga, M., Ishiguro, H., Iijima, Y., Inada, T., Watanabe, Y., Someya, T., Ujike, H., Iwata, N., et al. (2011) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31249 · Cited by 28
Sershen, H. W., Balla, A., Aspromonte, J., Xie, S., Cooper, T. B., & Javitt, D. C. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.07.011 · Cited by 28
How could N-Methyl-D-Aspartate Receptor Antagonists Lead to Excitation Instead of Inhibition?
Su, T., Lu, Y., Geng, Y., Lü, W., & Chen, Y. (2018) · Brain Science Advances · doi:10.26599/bsa.2018.2018.9050009 · Cited by 27
“Reduced NMDAR activity caused by its antagonists results in schizophrenia‐ like behaviors, which suggests that hypofunction of NMDARs might be one of the causes of schizo‐ phrenia, leading to the proposal of the NMDAR hypofunction hypothesis for schizophrenia [127, 128].”
BackgroundTobacco addiction: A biochemical model of nicotine dependence
Ortells, M. O., & Barrantes, G. E. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.11.004 · Cited by 31
A Computational Model for Spatial Working Memory Deficits in Schizophrenia
Cano-Colino, M., & Compte, A. (2012) · Pharmacopsychiatry · doi:10.1055/s-0032-1306314 · Cited by 28
“The glutamatergic hypothesis posits that hypofunctional NMDA receptor transmission in the neocortex is partly responsible for schizophrenia symptoms [26].”
BackgroundCai, H., Zhu, R., Huan-de, L., Zhang, X., Hu, L., Yang, W. Y., & Ye, H.-S. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.006 · Cited by 30
Williams, M. J. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.06.108 · Cited by 26
Mismatch-negativity (MMN) in animal models: Homology of human MMN?
Shiramatsu, T. I., & Takahashi, H. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107936 · Cited by 29
Bermingham, K. P., Doran, M. M., Bolger, F. B., & Lowry, J. P. (2022) · Analytica Chimica Acta · doi:10.1016/j.aca.2022.340205 · Cited by 29
Onkar, A., Khan, F., Goenka, A., Rajendran, R. L., Dmello, C., Hong, C. M., Mubin, N., Gangadaran, P., & Ahn, B. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c16839 · Cited by 27
Hasan, A., Misewitsch, K., Nitsche, M. A., Gruber, O., Padberg, F., Falkai, P., & Wobrock, T. (2013) · Brain stimulation · doi:10.1016/j.brs.2013.03.001 · Cited by 28
“In summary, a disturbed interplay between NMDARs and Gamma-aminobutyric acid (GABA)-receptors has been proposed to be responsible, at least in part, for the described pathophysiological state of impaired cortical plasticity in schizophrenia patients [28].”
Antipsychotic‐induced gene regulation in multiple brain regions
Girgenti, M. J., Nisenbaum, L. K., Bymaster, F. P., Terwilliger, R. Z., Duman, R. S., & Newton, S. S. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06585.x · Cited by 29
Sex-related patterns of the gut-microbiota-brain axis in the neuropsychiatric conditions
Manosso, L. M., Lin, J. H. X., Carlessi, A. S., Recco, K. C. C., Quevedo, J., Gonçalves, C. L., & Réus, G. Z. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.04.001 · Cited by 24
Paliperidone to Treat Psychotic Disorders
Minwalla, H. D., Wrzesinski, P., Desforges, A. D., Caskey, J., Wagner, B., Ingraffia, P., Patterson, J. C., Edinoff, A. N., Kaye, A. M., Kaye, A. D., et al. (2021) · Neurology International · doi:10.3390/neurolint13030035 · Cited by 27
“Evidence from multiple studies investigating genetics, imaging, NMDA receptor (NMDAR) antagonists and treatments that increase NMDAR function in schizophrenia patients all support the notion of NMDAR hypofunction contributing to symptoms [22].”
BackgroundSotoyama, H., Namba, H., Tohmi, M., & Nawa, H. (2023) · Biomolecules · doi:10.3390/biom13020372 · Cited by 26
“In general, the dopamine hypothesis for schizophrenia fails to illustrate the negative symptoms of this illness [145].”
BackgroundLuccini, E., Romei, C., & Raiteri, L. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05309.x · Cited by 24
Association of the DTNBP1 genotype with cognition and personality traits in healthy subjects
Kircher, T. T. J., Markov, V., Krug, A., Eggermann, T., Zerres, K., Nöthen, M. M., Skowronek, M. H., & Rietschel, M. (2009) · Psychological Medicine · doi:10.1017/s0033291709005388 · Cited by 24
“Finally, numerous studies to date have reported decreased dysbindin 1 expression in schizophrenia-related brain regions, such as the dorsolateral prefrontal cortex, hippocampus and midbrain (Numakawa et al. 2004; Talbot et al. 2004 ; Weickert et al. 2004 ; Coyle, 2006).”
BackgroundA Quantitative System Pharmacology Computer Model for Cognitive Deficits in Schizophrenia
Geerts, H., Roberts, P., & Spiros, Ä. (2013) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.12 · Cited by 26
“3 This study explores the possibility of developing a humanized computer simulation of a crucial part of the human cognitive processes, can be calibrated using clinical experiments and can deal with polypharmacy and new targets.”
Georgiev, D. D., Yoshihara, T., Kawabata, R., Matsubara, T., Tsubomoto, M., Minabe, Y., Lewis, D. A., & Hashimoto, T. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw022 · Cited by 24
Anti-N-Methyl-d-Aspartate Receptor Encephalitis
Hung, T., Foo, N.-H., & Lai, M. (2011) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2011.08.012 · Cited by 27
D-Amino-Acid Oxidase Inhibition Increases D-Serine Plasma Levels in Mouse But not in Monkey or Dog
Rojas, C. J., Alt, J., Ator, N. A., Thomas, A. G., Wu, Y., Hin, N., Wozniak, K. M., Ferraris, D. V., Rais, R., Tsukamoto, T., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.319 · Cited by 23
Understanding taurine CNS activity using alternative zebrafish models
Mezzomo, N. J., Fontana, B. D., Kalueff, A. V., Barcellos, L. J. G., & Rosemberg, D. B. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.04.012 · Cited by 23
Kuo, C.-Y., Lin, C., & Lane, H. (2022) · CNS Drugs · doi:10.1007/s40263-022-00959-5 · Cited by 23
“Ketamine and phencyclidine (PCP), two NMDAR antagonists, produced schizophrenia-like negative symptoms and cognitive impairment [12, 13].”
BackgroundSiekmeier, P. J., & vanMaanen, D. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058607 · Cited by 24
“or hypofunction of NMDA synaptic activity [6,7]; and (3)”
Exploring schizophrenia drug-gene interactions through molecular network and pathway modeling.
Putnam, D. K., Sun, J., & Zhao, Z. (2011) · PubMed · Cited by 23
Characterization of a Novel Mutation in SLC1A1 Associated with Schizophrenia
Afshari, P., Myles‐Worsley, M., Cohen, O. S., Tiobech, J., Faraone, S. V., Byerley, W., & Middleton, F. A. (2015) · Complex Psychiatry · doi:10.1159/000433599 · Cited by 24
Wang, Y., Zhao, H., Brewer, J. T., Li, H., Lao, Y., Amberg, W., Behl, B., Akritopoulou‐Zanze, I., Dietrich, J. D., Lange, U. E. W., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00295 · Cited by 53
Beyond quantitative and qualitative traits: three telling cases in the life sciences
Serpico, D. (2020) · Biology & Philosophy · doi:10.1007/s10539-020-09750-6 · Cited by 25
“Classical research on the neurobiology of schizophrenia attributes its typical symptoms to a disturbed and hyperactive dopaminergic signal transduction, but other studies have pointed at the involvement of the glutaminergic system and of malfunctioning in gliogenesis (see Coyle 2006; Dietz et al.”
BackgroundCui, K., Yu, Z., Xu, L., Jiang, W., Wang, L., Wang, X., Zou, D., Gu, J., Gao, F., Zhang, X., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1001869 · Cited by 22
“In conclusion, considering the acute effects, high face and construct validity of pharmacological NMDAR antagonism model (Corbett et al., 1995; Tsai and Coyle, 2002; Coyle, 2006; Frohlich and Van Horn, 2014), MK-801 is still widely utilized as a model for symptoms observed in schizophrenia (Ranson et al.”
MethodCrisafulli, C., Chiesa, A., Ronchi, D. D., Han, C., Lee, S.-J., Park, M. H., Patkar, A. A., Pae, C.-U., & Serretti, A. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.10.074 · Cited by 24
“receptors) [20] and is supported by a growing amount of empirical research suggesting a link between this neurotransmitter and SKZ [7].”
BackgroundSestito, R. S., Trindade, L. B., de Souza, R. G., Kerbauy, L. N., Iyomasa-Pilon, M. M., & Rosa, M. L. N. M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110385595 · Cited by 24
“There is an increasing research focus on the glutamate system in schizophrenia, from both pathogenic and therapeutic perspectives (Coyle, 2006; Harrison and Weinberger, 2005; Krystal et al., 2002; Lewis and Gonzalez-Burgos, 2006).”
BackgroundNovel approaches to drug design for the treatment of schizophrenia
Taly, A. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.821108 · Cited by 23
“3 NMDA receptors Schizophrenia has been proposed to be a glutamate disorder [63].”
BackgroundMabry, S. J., McCollum, L. A., Farmer, C. B., Bloom, E. S., & Roberts, R. C. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1615638 · Cited by 24
Gigg, J., McEwan, F., Smausz, R., Neill, J. C., & Harte, M. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119874446 · Cited by 25
“The sub-chronic phencyclidine (scPCP) model induces cognitive deficits similar to those in patients (Coyle, 2006) and was developed to model the N-methyl-D-aspartate (NMDA) receptor hypofunction hypothesis of schizophrenia (Javitt and Zukin, 1991; Krystal et al.”
ResultRedox Dysregulation in Schizophrenia: Genetic Susceptibility and Pathophysiological Mechanisms
Do, K. Q., Bovet, P., Cabungcal, J.-H., Conus, P., Gysin, R., Lavoie, S., Steullet, P., & Cuénod, M. (2009) · Springer eBooks · doi:10.1007/978-0-387-30410-6_8 · Cited by 26
Wirgenes, K. V., Djurovic, S., Agartz, I., Jönsson, E. G., Werge, T. M., Melle, I. S., & Andreassen, O. A. (2009) · Neuropsychobiology · doi:10.1159/000235799 · Cited by 24
“Glutamate mediates excitatory synaptic transmission in the central nervous system through several types of receptors. It is possible that abnormal glutamate function, as reduced N-methyl- D -aspartate (NMDA) receptor activation, could underlie some aspects of the cognitive deficits and positive and negative symptoms r…”
Background
Metadata
- Authors
- Coyle, J. T.
- Affiliations
- Harvard University (US)
- Corresponding author
- Coyle, Joseph T.
- ORCID
- Coyle, Joseph T.
- Venue
- Cellular and Molecular Neurobiology
- Published
- 2006-06-14
- Volume
- 26
- Issue
- 4-6
- Pages
- 363-382
- ISSN
- 0272-4340 (ISSN-L)
- 1573-6830
- PMC
- PMC11881825
- OpenAlex
- W2008639041
- Cited by
- 917
- References
- 159
- Citations by year
- 2026: 13 · 2025: 27 · 2024: 16 · 2023: 29 · 2022: 29 · 2021: 28 · 2020: 35 · 2019: 47 · 2018: 43 · 2017: 44 · 2016: 45 · 2015: 56 · 2014: 47 · 2013: 74 · 2012: 62
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Cellular and Molecular Neurobiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (P50MH060450, MH P50-60450, MH R01-572901)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- schizophrenia, glutamate, NMDA receptor, dopamine hypothesis, negative symptoms, cognitive impairment, NMDA receptor antagonists, schizophrenia risk genes, GABAergic interneurons, antipsychotic drugs, glutamatergic neurotransmission
- MeSH terms
- Animals, Dopamine, Glutamates, Humans, Models, Biological, Synaptic Transmission, Schizophrenia, Antipsychotic Agents, Receptors, N-Methyl-D-Aspartate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.